New cocktail of drugs takes on tough liver cancer
NCT ID NCT07052253
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing a combination of two immunotherapy drugs (AK104 and AK112) plus a targeted pill (TT-00420) in 100 people with advanced hepatocellular carcinoma that cannot be treated with local therapies. The main goal is to see how many patients' tumors shrink. Participants must not have had prior systemic cancer treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AK104, AK112 (immunotherapy drugs) and TT-00420 (tinengotinib, a targeted pill)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced liver cancer who have not had prior systemic therapy.
What could go wrong
This is an early-phase trial with only 100 participants, so results may not apply to everyone. The combination may cause significant side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union Hospital Tongji Medical College Huazhong University of Science And Technology
RECRUITINGWuhan, China, 430000, China
Contact
Contact